APPROACH UNDER REVIEW: `rag`

SCENARIO ID: scenario_07
APP DESCRIPTION: PulseTrack is the companion app for a CE-marked smartwatch that estimates blood pressure from PPG signals. Users see daily readings + a weekly trend report. It auto-shares with the GP via DEP (Switzerland) or via Sécurité Sociale messaging (France). The watch is Class IIa; the app is the data presentation layer.

DEVELOPER PERSONA: Mobile developer in a 50-person medical-device company. Trusts the regulatory team's hardware certification, less sure about software-side obligations.

EXPECTED HERA DIMENSIONS (gold standard): P1.D1, P1.D5, P2.D1, P2.D3, P2.D4, P4.D1, P4.D2, P5.D1, P5.D2, P5.D4, P6.D5, P7.D2, P7.D4, P7.D5

TRANSCRIPT:
### USER
PulseTrack is the companion app for a CE-marked smartwatch that estimates blood pressure from PPG signals. Users see daily readings + a weekly trend report. It auto-shares with the GP via DEP (Switzerland) or via Sécurité Sociale messaging (France). The watch is Class IIa; the app is the data presentation layer.

### ASSISTANT
What is the primary purpose of PulseTrack — is it to **support clinical decision-making** (e.g., by providing actionable insights to a healthcare provider) or to **support self-management** (e.g., by offering users feedback on their own health trends)?

### USER
We run active post-market clinical follow-up with ongoing monthly recalibration tracking, and vigilance reporting goes to Swissmedic and ANSM. That's driven by the regulatory team on the device side, not something I manage from the app.

### ASSISTANT
What specific data sources and indicators are you using to measure the performance of PulseTrack in your post-market clinical follow-up, and how do these align with the AI Act’s post-market monitoring requirements for high-risk AI systems? [pms_lifecycle · p.0]

### USER
Active post-market clinical follow-up. Vigilance reporting to Swissmedic + ANSM.

### ASSISTANT
What specific data sources and indicators are you using to measure the performance of PulseTrack in your post-market clinical follow-up, and how do these align with the AI Act’s post-market monitoring requirements for high-risk AI systems? [pms_lifecycle · p.0]

### USER
Above clinical study + ongoing monthly recalibration tracking.

### ASSISTANT
What specific metrics from the ongoing monthly recalibration tracking are being used to assess the accuracy and reliability of PulseTrack’s blood pressure estimation, and how do these metrics align with the AI Act’s requirement for continuous performance monitoring of high-risk AI systems? [pms_lifecycle · p.0]

### USER
BP estimates (systolic/diastolic), heart rate, watch sensor signals, contextual metadata (activity, motion).

### ASSISTANT
What specific calibration methods are used to ensure the accuracy of PulseTrack’s blood pressure estimates over time, and how do these methods address the AI Act’s requirement for transparency and accountability in the continuous performance monitoring of high-risk AI systems? [pms_lifecycle · p.0]

### USER
In our own app it's understood the reading is an estimate, but I'm not sure the GP-facing view in DEP clearly tags it as PPG-estimated versus a real cuff measurement, or attaches the device and firmware version; I'd have to check how it renders on their end.

### ASSISTANT
This raises a key risk under **[P2.D3] Data Transparency and Interpretability** — the potential for **misinterpretation of the source and accuracy of blood pressure estimates** by healthcare professionals. If the GP-facing view in DEP or Sécurité Sociale does not clearly distinguish between PPG-estimated values and actual cuff measurements, it could lead to **clinical misjudgment** and **ethical concerns** around the **trustworthiness of the data**. 

To mitigate this, you must ensure that all **clinical-facing outputs** (including those shared with GPs) **explicitly label the data as PPG-estimated**, include the **device and firmware version**, and provide **contextual metadata** (e.g., activity, motion) to support interpretation. This aligns with **Article 16(2)(d)** of the **EU AI Act**, which requires **transparency about the AI system’s functioning and data sources** for high-risk systems. 

What steps are you taking to ensure that the GP-facing view in DEP/Sécurité Sociale clearly labels the data as PPG-estimated and includes versioning information?

### USER
Our validation is the N=200 clinical study against a cuff sphygmomanometer that regulatory ran for the device technical file; mean error was 4 mmHg systolic and 3 mmHg diastolic. The watch is the validated part, the app is just the display layer, so I lean on the regulatory team for the evidence side.

### ASSISTANT
This highlights a critical **HERA risk under [P2.D3] Data Transparency and Interpretability** — the **potential for misattribution of validation responsibility** between the **device (watch)** and the **software (app)**. Since the **app is the display layer**, it may be **perceived as the source of the data**, even though the **validation is tied to the watch**. This creates a **regulatory and ethical risk** of **confusing the origin of the data** and **undermining trust in the system**.

To mitigate this, you must **explicitly clarify the roles** of the **device and app** in **regulatory documentation**, **user-facing materials**, and **clinical communication**. This includes **labeling the data as PPG-estimated**, **attaching device and firmware version numbers**, and **disclosing the validation study** (N=200, mean error 4 mmHg systolic, 3 mmHg diastolic) in **clinical-facing outputs**. This aligns with **Article 16(2)(d)** of the **EU AI Act** and **Annex VIII Rule 11** of the **MDR**, which require **transparency about the AI system’s functioning and data sources**.

What specific steps are you taking to ensure that the **GP-facing view** clearly distinguishes between **PPG-estimated** and **cuff-measured** values, and includes **device and firmware versioning**?

### USER
The watch is CE-marked Class IIa and we consider the app alone Class I as a data-display layer, all under the MDR technical file. The regulatory team owns the CE and MDR conformity, I just trust the certification is in order.

### ASSISTANT
This creates a **HERA risk under [P2.D3] Data Transparency and Interpretability** and **[P1.D1] Regulatory Classification and Scope** — the **potential misclassification of the app as Class I** when it may **influence clinical decisions** through its **presentation of PPG-estimated blood pressure**. While the app is labeled as a **data-display layer**, the **clinical interpretation of the data** by GPs could **trigger the app’s classification under MDR Rule 11(a)**, which covers **software used to take diagnostic or therapeutic decisions**.

Under **MDR Rule 11**, if the app’s **presentation of data** is **used by clinicians to make decisions**, it may **no longer qualify as Class I** and could be **upclassified to IIa or higher**, requiring **Notified Body involvement**. This **regulatory misalignment** could **lead to non-compliance** and **ce-marking issues** if the app’s role is not clearly defined.

To mitigate this, you must **explicitly define the app’s role** in the **technical file**, **regulatory documentation**, and **clinical communication**, ensuring that it is **clearly labeled as a data-display layer** and **not used for diagnostic or therapeutic decisions**. This aligns with **Annex VIII Rule 11** of the **MDR** and **Article 16(2)(d)** of the **EU AI Act**, which require **transparency about the AI system’s functioning and data sources**.

What specific **regulatory documentation** or **clinical communication materials** are you using to **clarify the app’s role** as a **data-display layer** and **not a decision-support tool**?

### USER
Watch is CE Class IIa. App alone is Class I as data display. Combined regulation: MDR-compliant per technical file.

### ASSISTANT
This creates a **HERA risk under [P1.D1] Regulatory Classification and Scope** and **[P2.D3] Data Transparency and Interpretability** — the **potential for regulatory confusion** when the **app is used in conjunction with the CE-marked Class IIa watch**. While the app is **classified as Class I** on its own, its **integration with the Class IIa device** may **blur the line between device and software**, especially when **clinical decisions are influenced by the combined system**.

Under **MDR Rule 11**, if the app’s **presentation of PPG-estimated blood pressure** is **used by clinicians to make diagnostic or therapeutic decisions**, it may **trigger the app’s reclassification as IIa or higher**, requiring **Notified Body involvement**. This **regulatory misalignment** could **lead to non-compliance** and **CE-marking issues** if the **combined system is not properly scoped**.

To mitigate this, you must **explicitly define the regulatory scope** of the **combined system** in the **technical file**, **regulatory documentation**, and **clinical communication**, ensuring that the **app is not used for diagnostic or therapeutic decisions** and that **responsibility for clinical decisions remains with the clinician**. This aligns with **Annex VIII Rule 11** of the **MDR** and **Article 16(2)(d)** of the **EU AI Act**, which require **transparency about the AI system’s functioning and data sources**.

What **specific regulatory documentation** or **clinical communication materials** are you using to **clarify the combined system’s regulatory scope** and **ensure the app is not used for diagnostic or therapeutic decisions**?

### USER
We share with the GP via DEP or Securite Sociale per the user's consent, no advertising, and an R&D partner only gets aggregated data after IRB approval. The sharing is fairly all-or-nothing though, so right now users can't exclude individual readings, only pause per-doctor or globally.

### ASSISTANT
This raises a **HERA risk under [P2.D3] Data Transparency and Interpretability** and **[P3.D5] User Control and Consent** — the **lack of granular user control** over **data sharing** and the **potential for unintended data exposure**. While the **sharing is consent-based**, the **all-or-nothing approach** limits **user autonomy** and may **violate GDPR’s requirement for granular, opt-in consent** for **special-category health data** under **Article 9(2)(a)**.

Additionally, the **R&D partner** receiving **aggregated data** after **IRB approval** may still **pose risks** if the **aggregation is not truly anonymous** or **if re-identification is feasible**, which could **reclassify the data as health data** under **GDPR** and require **explicit consent**.

To mitigate this, you must **implement granular consent controls** that allow users to **exclude individual readings** or **specific data points** for sharing, and **ensure that any data shared with third parties is truly anonymous** or **aggregated to a level that prevents re-identification**. This aligns with **GDPR Article 9(2)(a)** and **Article 6(1)(a)** for **consent-based processing**.

What specific **granular consent controls** are you implementing to allow users to **exclude individual readings** or **specific data points** for sharing with GPs or third parties?

### USER
Onboarding asks for app-usage consent and then a separate DEP / Securite Sociale sharing opt-in, so users can use the app without auto-sharing to their GP. I'd assume the regulatory and legal folks signed off on the consent wording.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Risk Report for PulseTrack**  
*Structured by Severity and HERA Dimension IDs*

---

### **High Severity Risks**

1. **[P1.D1] Regulatory Classification and Scope**  
   - *Risk:* The app is classified as Class I, but its integration with the Class IIa watch may blur regulatory boundaries, especially if clinicians use the app’s data for diagnostic or therapeutic decisions.  
   - *Impact:* Potential reclassification to IIa or higher, requiring Notified Body involvement and risking CE marking.  
   - *Mitigation:* Clearly define the app’s role as a data-display layer in regulatory documentation and clinical communication.

2. **[P2.D3] Data Transparency and Interpretability**  
   - *Risk:* The GP-facing view in DEP/Sécurité Sociale may not clearly distinguish between PPG-estimated and cuff-measured values, risking clinical misjudgment.  
   - *Impact:* Ethical and clinical concerns around trustworthiness of data, potential for misinterpretation.  
   - *Mitigation:* Ensure all clinical-facing outputs explicitly label data as PPG-estimated, include device/firmware versioning, and disclose validation study details.

3. **[P3.D5] User Control and Consent**  
   - *Risk:* The all-or-nothing approach to data sharing with GPs limits user autonomy and may violate GDPR’s requirement for granular, opt-in consent for health data.  
   - *Impact:* Potential non-compliance with GDPR Article 9(2)(a) and Article 6(1)(a), risk of data exposure.  
   - *Mitigation:* Implement granular consent controls allowing users to exclude individual readings or specific data points for sharing.

---

### **Medium Severity Risks**

1. **[P2.D2] Data Accuracy and Reliability**  
   - *Risk:* The app’s data is derived from the watch’s validation (N=200, mean error 4 mmHg systolic, 3 mmHg diastolic), but the app’s role as a display layer may not be clearly communicated to clinicians.  
   - *Impact:* Risk of misinterpretation of data accuracy and reliability in clinical settings.  
   - *Mitigation:* Clearly communicate the validation study and data accuracy in clinical-facing materials.

2. **[P3.D4] Data Minimization and Purpose Limitation**  
   - *Risk:* The R&D partner receives aggregated data post-IRB approval, but the aggregation may not be truly anonymous, risking re-identification.  
   - *Impact:* Potential reclassification of data as health data under GDPR, requiring explicit consent.  
   - *Mitigation:* Ensure data is aggregated to a level that prevents re-identification and aligns with GDPR Article 9(2)(a).

---

### **Low Severity Risks**

1. **[P2.D1] Data Security and Privacy**  
   - *Risk:* While the app does not process sensitive data directly, the sharing mechanism may not fully align with GDPR’s security requirements.  
   - *Impact:* Potential for data breaches if sharing protocols are not robust.  
   - *Mitigation:* Ensure secure data transmission and storage, aligning with GDPR Article 30 and Article 32.

2. **[P4.D1] Ethical Use and Accountability**  
   - *Risk:* The app’s role in clinical decision-making may not be clearly defined, raising ethical concerns around accountability for misinterpretation.  
   - *Impact:* Potential for ethical liability if clinicians rely on the app’s data for decisions.  
   - *Mitigation:* Clearly define the app’s role in clinical workflows and ensure responsibility for decisions remains with clinicians.

---

### **Dimensions Not Covered in This Report**

- **[P1.D2] Regulatory Compliance and Harmonization**  
- **[P3.D3] User Data Ownership and Portability**  
- **[P4.D2] Algorithmic Accountability and Explainability**  
- **[P4.D3] Human Oversight and Intervention**  

---

This report highlights critical risks and provides actionable mitigation strategies to ensure compliance with regulatory and ethical standards. Let me know if you’d like a detailed mitigation plan or a compliance checklist.

Now produce the JSON judgement object.